Why the study?
Anticoagulation research focuses on preventing systemic embolization and stroke, raising questions about the role of new oral anticoagulants in complex pro-coagulant conditions.
Answers are grounded in this paper and cite their sources.
This case report highlights the potential failure of dabigatran in preventing thromboembolic events in patients with antiphospholipid syndrome, suggesting warfarin should remain the mainstay of therapy for such multifactorial pro-coagulation states.
Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation.
No takes yet. Share an insight, caveat, or question.
Arcadi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: